J. Garcia‐Vargas

Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.

Martin Dreyling, Armando Santoro, Sirpa Leppä, Judit Demeter et autres

7555 Background: The efficacy of copanlisib, an intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, was demonstrated in the Phase II CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma (Dreyling et al. J Clin Oncol 2017). Copanlisib was approved by …

de, it, fi, hu, gb, kr, ca, il, sg, es, bg, us (code pays fourni par la source)

Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6‐year follow‐up of CHRONOS‐1

Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä et autres

Introduction: The phosphatidylinositol 3-kinase inhibitor copanlisib was approved for use in the US in 2017 as monotherapy in patients with relapsed follicular lymphoma (FL) who have progressed after ≥2 therapies based on results from the Phase II CHRONOS-1 study in patients with …

de, it, ca, fi, gb, kr, il, gr, hu, tr, ru, es, fr, Éthiopie, sg, us (code pays fourni par la source)

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Pier Luigi Zinzani, Muhıt Özcan, Marcelo Capra, Armando Santoro et autres

Introduction: As of 2021, four phosphatidylinositol 3-kinase (PI3K) inhibitors had received accelerated approval by the FDA for treatment of patients (pts) with indolent follicular lymphoma (FL) having received ≥2 systemic therapies. Recently, during confirmatory studies, three of the PI3K inhibitors have been …

it, tr, br, gr, pl, us, de (code pays fourni par la source)

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

Noriko Fukuhara, Dai Maruyama, Kiyohiko Hatake, Hirokazu Nagai et autres

The safety, efficacy, and pharmacokinetics of copanlisib were evaluated in this phase Ib/II study in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). The primary endpoint was safety at the recommended dose; efficacy endpoints included objective response rate (ORR), progression-free survival (PFS), …

jp, us (code pays fourni par la source)

A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma

Weiping Liu, Lingyan Ping, Yan Xie, Yingli Sun et autres

cn, Éthiopie, de, us (code pays fourni par la source)

Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Panayiotis Panayiotidis, George Follows, Luigina Mollica, Arnon Nagler et autres

Marginal zone lymphoma (MZL) is challenging to treat, with many patients relapsing following initial treatment. We report the long-term efficacy and safety of copanlisib, a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, in the subset of 23 patients with relapsed/refractory MZL treated in …

gr, gb, ca, il, tr, it, us, de (code pays fourni par la source)

260P A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)

Yuxin Song, W. Liu, Y. Niu, Galia Cisternas et autres

cn, de, us (code pays fourni par la source)

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä et autres

Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings regarding fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has low incidence of severe toxicities and no black box warnings, but chronic treatment effects were unknown. We provide …

de, it, ca, fi, gb, kr, il, gr, hu, tr, ru, fr, us (code pays fourni par la source)

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, Armando Santoro, Luigina Mollica, Sirpa Leppä et autres

Introduction: Copanlisib, a pan-class I phosphatidylinositol 3-kinase inhibitor, is approved in the US for the treatment of patients (pts) with relapsed follicular lymphoma (FL) who have received ≥2 prior systemic therapies; it also has Breakthrough Therapy designation for pts with relapsed marginal …

it, ca, fi, gb, de, kr, il, gr, hu, fr, us (code pays fourni par la source)

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, Panayiotis Panayiotidis, George Follows, Luigina Mollica et autres

Introduction: Marginal zone lymphoma (MZL) is an indolent B-cell malignancy comprising >10% of non-Hodgkin lymphomas. The Bruton's tyrosine kinase inhibitor ibrutinib was the first systemic therapy approved by the US Food and Drug Administration (FDA) for the treatment of patients (pts) with …

de, gr, gb, ca, il, tr, it, us (code pays fourni par la source)

COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA

P. Panayiotidis, Ádám Kellner, George Follows, Luigina Mollica et autres

Introduction: Marginal zone lymphoma (MZL) is an indolent B-cell malignancy, comprising >10% of non-Hodgkin lymphomas. In 2017, the FDA approved the BTK inhibitor ibrutinib for treatment of patients with relapsed/refractory MZL based on outcomes from a study of 60 patients, wherein an …

gr, hu, gb, ca, il, tr, it, de, us (code pays fourni par la source)

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB

Martin Dreyling, Armando Santoro, Sirpa Leppä, Judit Demeter et autres

Introduction: Patients (pts) with follicular lymphoma (FL) who have progression of disease within 24 months of first-line immunochemotherapy (POD24) have worse overall survival (OS). The Phase II CHRONOS-1 study in pts with relapsed or refractory indolent B-cell lymphoma showed durable responses with …

de, it, fi, hu, gb, kr, ca, il, sg, es, us (code pays fourni par la source)